Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cindy Neunert

Pediatric Hematology-Oncology Augusta, GA Medical Doctor

NPI 1689707507 CMS profile 1123068

1120 15Th St, Augusta, GA 30912

Open in the dashboard

General payments

$108,095

70 records reported · program years 2019–2025

Research payments

$18,816

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,701 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Cindy Neunert of Augusta, GA is reported in the CMS Open Payments database as having received $108,095 across 70 general payments and $18,816 in research payments paid to them. Separately, studies naming them as principal investigator received $16,701 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,075 9
2025 Research $2,250 1
2024 General $25,222 8
2023 General $10,798 4
2023 Research $16,566 1
2022 General $2,550 1
2021 General $5,083 3
2020 General $394 1
2019 General $44,973 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cindy Neunert
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Cindy Neunert were reported at $19,075. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Cindy Neunert Pediatric Hematology-Oncology median Middle half National median
2019 $44,973 $184 $69–$2,094 $163
2020 $394 $220 $37–$3,941 $114
2021 $5,083 $366 $63–$4,909 $132
2022 $2,550 $181 $66–$2,775 $149
2023 $10,798 $175 $62–$2,600 $160
2024 $25,222 $227 $66–$2,992 $164
2025 $19,075 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $80,993 51 payments
  2. Janssen Research & Development, LLC $9,622 8 payments
  3. Novartis Pharmaceuticals Corporation $6,269 4 payments
  4. Sobi, Inc $4,115 2 payments
  5. Dova Pharmaceuticals $3,080 1 payment
  6. Swedish Orphan Biovitrum AB $2,200 1 payment
  7. Argenx US, Inc. $1,250 1 payment
  8. Novo Nordisk Inc $394 1 payment
  9. Becton, Dickinson and Company $173 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $44,555 13 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,630 9 payments
  3. Travel and Lodging $18,757 26 payments
  4. Food and Beverage $1,758 21 payments
  5. Grant $394 1 payment
Products named General payments · program years 2019–2025
  1. LEMTRADA $40,601 38 payments
  2. Doptelet $7,195 3 payments
  3. PROMACTA Oncology $1,875 1 payment
  4. PROMACTA Oncology $1,830 1 payment
  5. VYVGART $1,250 1 payment
  6. WAYRILZ $4 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $16,566 1 payment
  2. Takeda Pharmaceuticals U.S.A., Inc. $2,250 1 payment

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record